It is orally active and initially received accelerated approval in 2012 for adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that are T315I-positive and are not candidates for other TK inhibitors. The gene discussed is TKT; the disease is acute lymphoblastic leukemia.